Circle Technologies

Our device, the Tekla, measures the concentration of biologic drugs in bioreactors in real-time. This helps manufacturers decrease costs and increase revenue.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Tulalip, WA, USA
  • Currency USD
  • Founded October 2011
  • Employees 1
  • Incorporation Type C-corp

Company Summary

The Tekla by Circle Technologies automatically measures the concentration of biologic drugs in bioreactors. This allows biologic manufacturers higher yields and lower manufacturing costs. We received a US Utility Patent in March 2020.

Ours is a high growth market: global biologic sales were $161 B (USD) in 2014, $200 B in 2017, with $250 B expected in 2020. Global spending on equipment for biologics was $15B in 2013; $20B expected in 2020.

Team

  • Andrew Sulya
    Founder, President, CEO

    Andrew has worked for 20 years in the biopharmaceutical industry, including positions at CMC Biologics making the drug Ixinity, and at Immunex making the blockbuster, Enbrel. He completed a PhD in Analytical Chemistry from the University of Washington's Center for Process Analysis and Control, designing real-time measurement devices. He received business training at Edmonds CC and Life Science Washington's Executive Mentorship Program.

Advisors

  • Bryan Brewer, Startup Coach, Fundraising Advisor for CEOs. Creator of the Minimum Fundable Company Test.
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free